Evidence map›Paper›PMID 18036263›Full record

ArticleBreast cancer research : BCR2007

Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?

Paul K Lovelock, Amanda B Spurdle, Myth T S Mok, Daniel J Farrugia, Sunil R Lakhani, Sue Healey, Stephen Arnold, Daniel Buchanan, kConFab Investigators, Fergus J Couch and 5 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Breast cancer research : BCR, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Considerations in assessing germline variant pathogenicity using cosegregation analysis.Genetics in medicine : official journal of the American College of Medical Genetics · 2020
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Cancer research · 2017
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 3 countries.

Paul K LovelockQueensland Institute of Medical Research, PO Royal Brisbane Hospital, Herston Road, Queensland 4029, Australia.
Amanda B Spurdle
Myth T S Mok
Daniel J Farrugia
Sunil R Lakhani
Sue Healey
Stephen Arnold
Daniel Buchanan
kConFab Investigators
Fergus J Couch
Beric R Henderson
David E Goldgar
Sean V Tavtigian
Georgia Chenevix-Trench
Melissa A Brown
QIMR Berghofer Medical Research Institute · AUMayo Clinic · USUniversity of Queensland · AUWestmead Institute · AUCentre International de Recherche sur le Cancer · FRPeter MacCallum Cancer Centre · AURoyal Brisbane and Women's Hospital · AUUniversity of Utah · US

Funding

The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast CancerP50CA116201 · NCI · MAYO CLINIC ROCHESTER · PI PETER C LUCAS · 2005 to 2026
$49.9M
NCI NIH HHS P50 CA116201
6 · The paper itself

Abstract

introductionMany of the DNA sequence variants identified in the breast cancer susceptibility gene BRCA1 remain unclassified in terms of their potential pathogenicity. Both multifactorial likelihood analysis and functional approaches have been proposed as a means to elucidate likely clinical significance of such variants, but analysis of the comparative value of these methods for classifying all sequence variants has been limited.

methodsWe have compared the results from multifactorial likelihood analysis with those from several functional analyses for the four BRCA1 sequence variants A1708E, G1738R, R1699Q, and A1708V.

resultsOur results show that multifactorial likelihood analysis, which incorporates sequence conservation, co-inheritance, segregation, and tumour immunohistochemical analysis, may improve classification of variants. For A1708E, previously shown to be functionally compromised, analysis of oestrogen receptor, cytokeratin 5/6, and cytokeratin 14 tumour expression data significantly strengthened the prediction of pathogenicity, giving a posterior probability of pathogenicity of 99%. For G1738R, shown to be functionally defective in this study, immunohistochemistry analysis confirmed previous findings of inconsistent 'BRCA1-like' phenotypes for the two tumours studied, and the posterior probability for this variant was 96%. The posterior probabilities of R1699Q and A1708V were 54% and 69%, respectively, only moderately suggestive of increased risk. Interestingly, results from functional analyses suggest that both of these variants have only partial functional activity. R1699Q was defective in foci formation in response to DNA damage and displayed intermediate transcriptional transactivation activity but showed no evidence for centrosome amplification. In contrast, A1708V displayed an intermediate transcriptional transactivation activity and a normal foci formation response in response to DNA damage but induced centrosome amplification.

conclusionThese data highlight the need for a range of functional studies to be performed in order to identify variants with partially compromised function. The results also raise the possibility that A1708V and R1699Q may be associated with a low or moderate risk of cancer. While data pooling strategies may provide more information for multifactorial analysis to improve the interpretation of the clinical significance of these variants, it is likely that the development of current multifactorial likelihood approaches and the consideration of alternative statistical approaches will be needed to determine whether these individually rare variants do confer a low or moderate risk of breast cancer.

Indexed as

Genes, BRCA1Mutation, MissenseAlanineArginineBiomarkers, TumorBreast NeoplasmsCentrosomeDNA, ComplementaryFactor Analysis, StatisticalFemaleGenetic Predisposition to DiseaseGlutamic AcidGlutamineGlycineHumansImmunohistochemistryAlanineArginineBiomarkers, TumorDNA, ComplementaryGlutamic AcidGlutamineGlycineKeratinsReceptors, EstrogenValine

Identifiers

PMID18036263
PMCPMC2246181
OpenAlexW2170803114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.